MY PICK IS ELN

[lak]

Move over, King! Here I come to junk up your thread!

Bile--

One way or another, a big move is coming.

THanks for that chart...........
that is why I stuck with a small postion.......... small risk........ possibly nice reward.

[Runner]

ELN intra day chart

Something is brewing here!!

[Websman]

ELN intra day chart

Something is brewing here!!

Just watch this baby fly when Tysabri is re-introduced.

[Tormentos]

Im thinking about adding some more shares tomorrow, any opinions? Right now my ave. share price is 6.69. I pulled out of NGPS yesterday so I have some extra $ to invest.

[lak]

Just watch this baby fly when Tysabri is re-introduced.

Now that's the attitude!

[New-born baby]

Just watch this baby fly when Tysabri is re-introduced.

Now that's the attitude!

I am going to make my first $$BILLION$$ off this one!

Im thinking about adding some more shares tomorrow, any opinions? Right now my ave. share price is 26.12. I pulled out of GooG yesterday so I have some extra $$ to invest.

Here's the chart:

[lak]

Sorry to rain on your party. Here's the chart, and it says $5.60 is in the cards for ELN. Why? I don't know; I didn't write the chart. I am just reading the chart for you. Could be it has something to do with Tysabri.

Thanks for the chart...... and the comments. I read your posts and pay attention. Dow Theory is a bitch ain't it?

[New-born baby]

Just having fun

LAK,

I hope all goes well with all our MM types. But I had to have a little fun with this one today. ELN is a wild stock, and could pull a headfake here.
.
Did you catch all the monikers? And here's the quote I like best:
Originally Posted by Ty SOB Ray
Im thinking about adding some more shares tomorrow, any opinions? Right now my ave. share price is 26.12. I pulled out of GooG yesterday so I have some extra $$ to invest.

"Pulled out of GooG . . . . "





Best to you.

[Websman]

No need to worry about daily price changes. ELN has a bright future with or without Tysabri...


Contact: Lisa Rossi Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.
Telephone: 412-647-3555
Fax: 412-624-3184

UNIVERSITY OF PITTSBURGH RESEARCHERS TO TEST INVESTIGATIONAL TREATMENT FOR ALZHEIMER’S DISEASE

PITTSBURGH, June 24, 2004 – The Alzheimer’s Disease Research Center (ADRC) at the University of Pittsburgh has been chosen as a research site to participate in the first human clinical trials of an investigational treatment for Alzheimer’s disease (AD).

The investigational drug known as AAB-001, a specific antibody to beta-amyloid, is thought to work by removing a protein called beta-amyloid, which is present only in small amounts in the normal brain but is greatly increased in the brains of AD patients. Researchers believe the amyloid plaques result from unknown genetic and environmental miscues that cause the brain to produce and deposit it in clumps. The accumulation of amyloid plaque is believed to cause the death of neurons, in part by stimulating another abnormal protein metabolism known as neurofibriallary tangles in neurons, resulting in memory loss. As the disease progresses, more and more plaques accumulate and patients suffer greater cognitive impairments.

“Working with AAB-001 gives us an exciting opportunity to continue our Alzheimer’s disease research,” said Steven T. DeKosky, M.D., professor of neurology, psychiatry, neurobiology and human genetics at the University of Pittsburgh School of Medicine and director of the ADRC. “If the safety data from these initial clinical tests are positive, larger clinical trials may be initiated to determine whether AAB-001 can be a potential treatment breakthrough.”

The drug, AAB-001, is the first of its kind to emerge for testing since trials of an anti-amyloid vaccine were suspended two years ago due to medical complications. AAB-001 is a novel monoclonal antibody, using synthetically engineered antibodies directed to seek out and reduce amyloid. The monoclonal antibody is intended to provide the patient’s immune system with the capability to respond to the amyloid, a key difference from the earlier vaccine strategy. In that study, the vaccine, AN-1792, stimulated the patient to mount their own immune response, that is, produce their own antibodies.

The primary purpose of this study is to evaluate the safety of AAB-001 and how well increasing doses of AAB-001 (in successive groups of subjects) are tolerated. A secondary purpose of the study is to measure the amount of AAB-001 in the blood, and how long it remains in the blood over time.

AAB-001 is an investigational drug and is not currently approved for commercial use by the U.S. Food and Drug Administration. In this study, AAB-001 is being given to humans for the first time. The study is sponsored by Wyeth Research, and is an initiative of the Elan/Wyeth Alzheimer’s Immunotherapy Program.

The study has so far enrolled three patients in Pittsburgh and will eventually include approximately eight. Participants must meet criteria outlined in the study protocol.

About the University of Pittsburgh Medical Center

The University of Pittsburgh Medical Center is a non-profit, comprehensive academic health care system affiliated with the University of Pittsburgh Schools of the Health Sciences. Their combined mission is to provide quality patient care, educate the next generation of health care professionals and advance biomedical knowledge through basic and clinical research.

The ADRC at the University of Pittsburgh was established in 1985 by a grant from the National Institute on Aging as a mechanism for integrating, coordinating and supporting new and ongoing research in Alzheimer’s and aging.

[kingofthehill]

http://www.boston.com/news/local/massachusetts/articles/2005/06/24/a_drug____and_hopes____on_hold/?page=full

[kingofthehill]

Contact: Lisa Rossi Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.
Telephone: 412-647-3555
Fax: 412-624-3184

UNIVERSITY OF PITTSBURGH RESEARCHERS TO TEST INVESTIGATIONAL TREATMENT FOR ALZHEIMER’S DISEASE

PITTSBURGH, June 24, 2004 – The Alzheimer’s Disease Research Center (ADRC) at the University of Pittsburgh has been chosen as a research site to participate in the first human clinical trials of an investigational treatment for Alzheimer’s disease (AD).

The investigational drug known as AAB-001, a specific antibody to beta-amyloid, is thought to work by removing a protein called beta-amyloid, which is present only in small amounts in the normal brain but is greatly increased in the brains of AD patients. Researchers believe the amyloid plaques result from unknown genetic and environmental miscues that cause the brain to produce and deposit it in clumps. The accumulation of amyloid plaque is believed to cause the death of neurons, in part by stimulating another abnormal protein metabolism known as neurofibriallary tangles in neurons, resulting in memory loss. As the disease progresses, more and more plaques accumulate and patients suffer greater cognitive impairments.

“Working with AAB-001 gives us an exciting opportunity to continue our Alzheimer’s disease research,” said Steven T. DeKosky, M.D., professor of neurology, psychiatry, neurobiology and human genetics at the University of Pittsburgh School of Medicine and director of the ADRC. “If the safety data from these initial clinical tests are positive, larger clinical trials may be initiated to determine whether AAB-001 can be a potential treatment breakthrough.”

The drug, AAB-001, is the first of its kind to emerge for testing since trials of an anti-amyloid vaccine were suspended two years ago due to medical complications. AAB-001 is a novel monoclonal antibody, using synthetically engineered antibodies directed to seek out and reduce amyloid. The monoclonal antibody is intended to provide the patient’s immune system with the capability to respond to the amyloid, a key difference from the earlier vaccine strategy. In that study, the vaccine, AN-1792, stimulated the patient to mount their own immune response, that is, produce their own antibodies.

The primary purpose of this study is to evaluate the safety of AAB-001 and how well increasing doses of AAB-001 (in successive groups of subjects) are tolerated. A secondary purpose of the study is to measure the amount of AAB-001 in the blood, and how long it remains in the blood over time.

AAB-001 is an investigational drug and is not currently approved for commercial use by the U.S. Food and Drug Administration. In this study, AAB-001 is being given to humans for the first time. The study is sponsored by Wyeth Research, and is an initiative of the Elan/Wyeth Alzheimer’s Immunotherapy Program.

The study has so far enrolled three patients in Pittsburgh and will eventually include approximately eight. Participants must meet criteria outlined in the study protocol.

About the University of Pittsburgh Medical Center

The University of Pittsburgh Medical Center is a non-profit, comprehensive academic health care system affiliated with the University of Pittsburgh Schools of the Health Sciences. Their combined mission is to provide quality patient care, educate the next generation of health care professionals and advance biomedical knowledge through basic and clinical research.

The ADRC at the University of Pittsburgh was established in 1985 by a grant from the National Institute on Aging as a mechanism for integrating, coordinating and supporting new and ongoing research in Alzheimer’s and aging.

Print-friendly version of news release

[lak]

LAK,

I hope all goes well with all our MM types. But I had to have a little fun with this one today. ELN is a wild stock, and could pull a headfake here.
.
Did you catch all the monikers? And here's the quote I like best:
Originally Posted by Ty SOB Ray
Im thinking about adding some more shares tomorrow, any opinions? Right now my ave. share price is 26.12. I pulled out of GooG yesterday so I have some extra $$ to invest.

"Pulled out of GooG . . . . "





Best to you.

Yep I remember seeing that.........
Wild is an understatement........ that is why I went small share count with a stop added in....... I left the stop with plenty of space....... so it won't hit right away and I am watching it. I just think if it turns it could turn big..... then again it could crash at any minute.......
I like the crew here as well. Have learned quite a bit watching people's posts here. I enjoy it and it makes me want to learn more each time I stop in.
best to you as well.

[New-born baby]

Glad you are here

Yep I remember seeing that.........
Wild is an understatement........ that is why I went small share count with a stop added in....... I left the stop with plenty of space....... so it won't hit right away and I am watching it. I just think if it turns it could turn big..... then again it could crash at any minute.......
I like the crew here as well. Have learned quite a bit watching people's posts here. I enjoy it and it makes me want to learn more each time I stop in.
best to you as well.

Lak,

We are glad to have you here. Everybody here loves everybody else, and is rooting for their success. And there's a little humor, some good posts/warnings/encouragement/instruction.

Best to you,

[lak]

All signs pointing to a continual decline here............ will keep it on the primary watchlist.

[New-born baby]

Oh no!

All signs pointing to a continual decline here............ will keep it on the primary watchlist.

Shouldn't have pulled out of GooG.